Article

Human genetics of SOST

Department of Medical Genetics, University and University Hospital of Antwerp, Antwerp, Belgium.
Journal of musculoskeletal & neuronal interactions (Impact Factor: 2.4). 10/2006; 6(4):355-6.
Source: PubMed
Download full-text

Full-text

Available from: Wim Van Hul, Oct 17, 2014
0 Followers
 · 
65 Views
  • Source
    Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research 04/2009; 24(3):373-85. DOI:10.1359/jbmr.090105 · 6.59 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: We examined the effects that ovariectomy had on sclerostin mRNA and protein levels in the bones of 8-week-old mice that were either sham-operated (SHAM) or ovariectomized (OVX) and then sacrificed 3 or 6 wks. later. In this model bone loss occurred between 3 and 5 wks. post-surgery. In calvaria OVX significantly decrease sclerostin mRNA levels at 6 wks. post-surgery (by 52%) but had no significant effect at 3 wks. In contrast, sclerostin mRNA levels were significantly lower in OVX femurs at 3 wks. post-surgery (by 53%) but equal to that of SHAM at 6 wks. The effects of OVX on sclerostin were not a global response of osteocytes since they were not mimicked by changes in the mRNA levels for 2 other relatively osteocyte-specific genes: DMP-1 and FGF-23. Sclerostin protein decreased by 83% and 60%, respectively at 3 and 6 wks. post-surgery in calvaria and by 38% in lumbar vertebrae at 6 wks. We also detected decreases in sclerostin by immunohistochemistry in cortical osteocytes of the humerus at 3 wks. post-surgery. However, there were no significant effects of OVX on sclerostin protein in femurs or on serum sclerostin at 3 and 6 wks. post-surgery. These results demonstrate that OVX has variable effects on sclerostin mRNA and protein in mice, which are dependent on the bones examined and the time after surgery. Given the discrepancy between the effects of OVX on serum sclerostin levels and sclerostin mRNA and protein levels in various bones, these results argue that, at least in mice, serum sclerostin levels may not accurately reflect changes in the local production of sclerostin in bones. Additional studies are needed to evaluate whether this is also the case in humans. © 2012 American Society for Bone and Mineral Research.
    Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research 03/2013; 28(3). DOI:10.1002/jbmr.1773 · 6.59 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Multiple myeloma (MM) is a plasma cell malignancy where plasma cells are increased in the bone marrow (BM) and usually do not enter peripheral blood, but produce harmful factors creating problems in these patients (e.g. malignant plasma cells over activate osteoclasts and inhibit osteoblasts with factors like RANKL and DKK). These factors are a main cause of bone lesion in MM patients. Recently SOST gene which responsible to encodes the sclerostin protein was identify. This protein specifically inhibits Wnt signaling in osteoblasts (inhibition of osteoblast differentiation and proliferation) and decrease bone formation and can also cause bone lesion in MM patients. In this experimental study, human myeloma cell lines (U266 b1) were purchased from Pasteur Institute of Iran. Samples consisted of BM aspirates from the iliac crest of MM patients. BM with more than 70% plasma cell were selected for our study (6 patients) and one healthy donor. RNA extraction was done with Qiagen kit. was undertaken on mRNA of samples and cell lines. Also we purchased unrestricted somatic stem cells from Bonyakhte Company to evaluate the effect of soluble factors from myeloma cell lines on osteogenic differentiation medium. Our results showed that SOST is expressed significantly in primary myeloma cells derived from MM patients and myeloma cell lines. In other words, patients with more bone problems, express SOST in their plasma cells at a higher level. In addition, myeloma cells inhibit osteoblast differentiation in progenitor cells from umbilical cord blood stem cell (UCSC) in osteogenic inducing medium. There are many osteoblast maturation inhibitory factors such as DKK, Sfrp and Sclerostin that inhibit maturation of osteoblast in bone. Among osteoblast inhibitory agents (DKK, Sfrp, Sclerostin) sclerostin has the highest specificity and therefore will have less side effect versus non-specific inhibitory agents. Our results also show that based on SOST expression in MM, there is a potential to inhibit sclerostin with antibody or alternative methods and prevent bone lesion in MM patients with the least side effect.
    Cell Journal 08/2013; 15(3):266-71. · 0.46 Impact Factor
Show more